A Phase I and Randomized Phase II Multicenter Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 16 Feb 2019
At a glance
- Drugs Cabozantinib (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Feb 2019 Results of pooled analysis of phase 1/2 study assessing safety and efficacy of cabozantinib plus docetaxel and prednisone versus docetaxel and prednisone alone in metastatic castrate-resistant prostate cancer presented at the 2019 Genitourinary Cancers Symposium
- 17 Jan 2019 Status changed from active, no longer recruiting to completed.
- 15 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Jul 2019.